First Hawaiian Bank Sells 662 Shares of IQVIA Holdings Inc. (NYSE:IQV)

First Hawaiian Bank lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,628 shares of the medical research company’s stock after selling 662 shares during the quarter. First Hawaiian Bank’s holdings in IQVIA were worth $2,164,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of IQV. Old North State Trust LLC boosted its holdings in IQVIA by 342.2% during the first quarter. Old North State Trust LLC now owns 597 shares of the medical research company’s stock worth $27,000 after purchasing an additional 462 shares during the last quarter. Hanson & Doremus Investment Management boosted its holdings in IQVIA by 300.0% during the first quarter. Hanson & Doremus Investment Management now owns 144 shares of the medical research company’s stock worth $29,000 after purchasing an additional 108 shares during the last quarter. AllSquare Wealth Management LLC bought a new stake in IQVIA during the first quarter worth $36,000. Live Oak Investment Partners bought a new stake in IQVIA during the fourth quarter worth $41,000. Finally, Headlands Technologies LLC lifted its holdings in IQVIA by 62.3% during the first quarter. Headlands Technologies LLC now owns 224 shares of the medical research company’s stock worth $45,000 after acquiring an additional 86 shares during the period. Institutional investors own 86.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Stifel Nicolaus raised their price objective on shares of IQVIA from $255.00 to $281.00 and gave the stock a “buy” rating in a report on Wednesday, August 2nd. Truist Financial increased their price objective on IQVIA from $244.00 to $260.00 and gave the company a “buy” rating in a report on Tuesday, July 18th. Barclays increased their price objective on IQVIA from $230.00 to $250.00 in a report on Tuesday, June 27th. Morgan Stanley upped their price objective on shares of IQVIA from $220.00 to $240.00 and gave the company an “overweight” rating in a report on Wednesday, August 2nd. Finally, HSBC began coverage on shares of IQVIA in a report on Wednesday, September 6th. They set a “buy” rating and a $260.00 price objective on the stock. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $252.00.

IQVIA Stock Performance

NYSE:IQV opened at $212.96 on Friday. The business’s 50-day moving average price is $220.22 and its two-hundred day moving average price is $208.08. IQVIA Holdings Inc. has a twelve month low of $165.75 and a twelve month high of $241.86. The stock has a market cap of $39.00 billion, a P/E ratio of 36.65, a PEG ratio of 2.19 and a beta of 1.37. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 2.16.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, August 1st. The medical research company reported $2.22 EPS for the quarter, topping analysts’ consensus estimates of $2.09 by $0.13. The firm had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.70 billion. IQVIA had a net margin of 7.47% and a return on equity of 30.14%. As a group, equities analysts predict that IQVIA Holdings Inc. will post 9.24 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.